myNEO Therapeutics
Founded 2018 · 18 employees on LinkedIn · 1 known investors
myNEO develops the ImmunoEngine platform, a modular suite of AI-driven technologies for immune target discovery, prioritization, and optimization, covering personalized neoantigen discovery, codon optimization, construct design, ADA risk prediction, and epitope screening. It serves biologics developers, vaccine and T-cell therapy developers, and pharma partners building immunotherapies including cancer vaccines and biologics.
Investors · 1
Frequently asked questions
- What does myNEO Therapeutics do?
- myNEO develops the ImmunoEngine platform, a modular suite of AI-driven technologies for immune target discovery, prioritization, and optimization, covering personalized neoantigen discovery, codon optimization, construct design, ADA risk prediction, and epitope screening. It serves biologics developers, vaccine and T-cell therapy developers, and pharma partners building immunotherapies including cancer vaccines and biologics.
- Who are myNEO Therapeutics's investors?
- myNEO Therapeutics's investors include Novalis Biotech.